Bio & Pharma
Hanall Biopharma invests in Interon Labs for brain disease treatments
Interon focuses on developing therapeutics for severe autism spectrum disorder by modulating the neuro-immune axis pathway
By Feb 13, 2023 (Gmt+09:00)
1
Min read
Most Read
LG Chem to sell water filter business to Glenwood PE for $692 million


Kyobo Life poised to buy Japan’s SBI Group-owned savings bank


KT&G eyes overseas M&A after rejecting activist fund's offer


StockX in merger talks with Naver’s online reseller Kream


Mirae Asset to be named Korea Post’s core real estate fund operator



South Korean pharmaceuticals firm Hanall Biopharma Co. is investing in Interon Laboratories, a US biotech firm that finds and develops treatments for brain diseases, the Korean company said on Feb. 10.
The investment will fund Interon's ongoing development of its lead programs targeting a range of neurological and immune disorders.
Interon focuses on developing therapeutics for severe autism spectrum disorder (ASD) by modulating the neuro-immune axis pathway.
Interon will use the technology to proceed with pre-clinical research on developing therapies for neurological disorders, beginning with ASD.
"Interon's innovative approach to treating brain diseases through control of the immune system gives new hope for treating incurable diseases, beyond existing research methods," said Jung Seung-won, CEO of Hanall Biopharma. "We look forward to a range of collaborations with Interon."
Write to Jae-Yong Han at jyhan@hankyung.com
More to Read
-
RoboticsKoh Young’s medical robot conducts 100 brain surgeries a year
Jan 26, 2022 (Gmt+09:00)
1 Min read -
Bio & PharmaCENYX Biotech, developing treatment for brain damage with ROS-scavenging, nano-sized heavy metals
Dec 26, 2022 (Gmt+09:00)
7 Min read
Comment 0
LOG IN